Anthropic plans to list under the ticker symbol “ANT.”
SUCCESS
The American Consumer: Spending Strong But Finances Are Uneven
While affluent households maintain strong discretionary purchases, price-conscious shoppers increasingly seek bargains at discount stores due to higher costs.
Macy’s is selling a fleece vest for $25 in 8 colors
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.
Why we love this deal
We’re at the point in fall when some days feel extra chilly, and others feel warmer, almost like a hint of summer in the middle of autumn. Layers are extra important during these times, as you can create the perfect warmth with the right pieces. A fleece jacket is a popular pick that can keep you cozy throughout the season, but another fall essential that should be in your closet is a fleece vest. It’s layerable and versatile, providing enough warmth without causing you to overheat or adding extra bulk to an outfit.
The Style and Co Polar Fleece Vest is a wonderful option that shoppers say is a “nice layer for chilly days,” and it’s on sale for only $25. During Macy’s Friends and Family Sale, you can get it for 44% off. The code to get the discount, FRIEND, is already applied to your cart, so you don’t have to do anything aside from adding it to your cart before the deal ends on Tuesday, Nov. 3.
Style & Co Polar Fleece Vest, $25 (was $45) at Macy’s
Courtesy of Macy’s
Shop at Macy’s
Why do shoppers love it?
Creating the perfect fall outfit is about using layers that look good while providing warmth. A fleece vest, like this affordable pick from Macy’s, does just that. Made of 100% polyester, the fleece vest adds a cozy layer that can help you stay warm during chilly or slightly warmer fall days. The mock neck is a stylish design feature, which also keeps your neck warm and retains heat. The two side pockets provide extra space to tuck your hands into when it’s extra cold, or to hold small items, like keys or a wallet.
This fleece vest is a great option that you can use all fall and winter long, making it a versatile addition to any closet. During warmer fall days, you can wear it with a T-shirt or a long-sleeve shirt. It would also pair well with a plaid flannel, a comfortable hoodie, or knit sweater. When the temperature really starts to drop in late fall and winter, it can be worn over a thicker jacket or puffer coat for even more warmth.
The Macy’s exclusive vest is available in regular, petite, and plus silhouettes, with sizes ranging from XS to XXL. It comes in eight colors, too, so you can add multiple to your cart to pair with more fall and winter outfits.
Related: Walmart is selling a cozy 2-piece lounge set for $23 in 12 colors
Details to know
Sizes: From women’s XS to XXL.
Types: Regular, petite, and plus.
Colors: Eight.
Macy’s shoppers noted how “soft” and “warm” the vest is, without it being too bulky. “Keeps me warm on these brisk autumn days,” one customer said. Another who shared that they bought it for a trip said, “I wanted something warm for layering and not bulky for packing or under a coat. It is soft and comfortable. I’m going back to get another one in a different color.”
Shop more deals
White Mark Sherpa Vest, $30 (was $58) at Macy’s
Style & Co Quilted Mock-Neck Vest, $31 (was $55) at Macy’s
Columbia Benton Springs Fleece Vest, $42 (was $60) at Macy’s
Stay warm during the fall and winter months with the Style and Co Polar Fleece Vest while it’s on sale for only $25.
Bank of America backs Pharvaris on breakthrough for rare swelling disease
Pharvaris (PHVS) is a biotech company developing pills for hereditary angioedema (HAE).
HAE is rare, and people with it often develop sudden swelling in the face, hands, stomach, or throat. Unfortunately, when the swelling happens in the throat, it can be deadly.
Creating a pill for a disease that can suddenly threaten a life will be a massive step forward for both the people who have it and the pharmaceutical company. Pharvaris seems to be making good progress, which is one reason Bank of America upgraded PHVS to a Buy rating from Neutral on Oct. 23.
In addition to the change in rating, the bank also kept its price target at $44. Although BofA didn’t raise its price target, the stock closed that day at $31.41, suggesting the bank still sees substantial upside.
Also read: Novo Nordisk’s CEO delivered a warning that sank its stock by 8%
BofA sees PHVS as a bargain after the September slide
Pharvaris shared strong trial results in September, which usually lift a share, but surprisingly, PHVS pulled back weeks later after the stock initially rose.
That’s why analyst Tazeen Ahmad noted in a BofA Global Research report shared with me that the drop looked like a good chance to buy. There is no change in the stock’s fundamentals, Benzinga reported.
“We upgrade PHVS to Buy as the recent pullback creates an attractive entry point with clinical risk largely removed,” Ahmad wrote in her note. She said feedback from doctors who treat HAE has been encouraging, adding that “our post-data KOL checks remain positive.”
Pharvaris is testing an oral pill for people living with hereditary angioedema, a rare swelling disorder.SOPA Images / Getty Images
What makes deucrictibant stand out in HAE treatment
The drug that showed strong trial results and led to the upgrade is called deucrictibant, or deucri for short. HAE affects about 1 in 50,000 people, and there are roughly 7,500 patients in the United States, according to the Bank of America note.
There are already prevention treatments for HAE. However, deucri stands out because it is a pill with two forms, while most of the other options are injections, which many patients find hard to stick with over the years.
The main oral option currently on the market is BioCryst’s (BCRX) Orladeyo, which BofA says reduces attack rates by about 44% to 50%.
Related: Medicare just handed Eli Lilly a massive weight-loss win
However, deucrictibant’s recent clinical trial showed even better results.
In the CHAPTER-3 phase 3 trial reported by Pharvaris, deucrictibant cut attacks by 83% compared with placebo. That is closer to what the leading injectables can do.
If the FDA approves deucri, patients could swallow one pill to prevent HAE attacks and another to stop an attack that is already starting. “KOLs see deucri as the likely preferred 1L oral option for new prophy patients,” Ahmad noted.
Two 2027 FDA decisions that could reset the stock
The FDA will decide about the on-demand version of deucrictibant on April 23, 2027. Pharvaris also plans to file for approval of the prevention version in the first half of 2027, Investing.com reported.
Those two decisions could impact the stock positively or negatively.
More Pharmaceuticals Stocks:
Peptide patients paying up to $1,500 a month face an FDA problem
BofA thinks Wall Street is underestimating one J&J drug
Jazz Pharmaceuticals gets Cramer’s vote of confidence
BofA expects a positive result, and the bank even predicts about $917 million in peak sales for the prevention product, with a 2028 launch target.
The firm believes deucrictibant could capture 30% to 50% of the oral prevention market over time if real-world interest from doctors holds up.
What PHVS investors should consider
BofA flagged some possible risks that could still affect the stock, including long-term safety signals and slow adoption among patients who don’t like to switch drugs often. The note also mentioned that competition from newer injections that patients only have to take once in a while should also be considered.
In addition, the FDA hasn’t yet approved deucrictibant, and a single clinical setback or missed approval could quickly send the stock falling.
So, as I usually suggest, if you want to buy in now, start off small and wait for clear FDA approval before going all in. That could help reduce your risk.
More Stocks NewsNvidia-backed Lumentum stock surges 10% as Wall Street sees more upsideMusk predicts ‘guppy-level death’ as SpaceX closes $40B GPU dealScott Bessent just opened the door to a major gold comebackWarren Buffett’s former fintech investment plunges 20%
Nvidia-backed Lumentum stock surges 10% as Wall Street sees more upside
Lumentum Holdings (LITE) shares jumped about 10% to $819.98 on Monday, Oct. 26, after StoneX initiated coverage of the optical networking company with a Buy rating and a $1,200 price target.
The rally spread to other optical networking stocks. Coherent (COHR) and Applied Optoelectronics (AAOI) gained about 7.6% and 10%, respectively, while the Roundhill Photonics & Optics ETF (LYTE) rose 5%.
StoneX said Lumentum occupies “critical scarcity points” in high-speed indium phosphide lasers, cloud transceivers and optical circuit switches, The Fly reported.
The analyst also highlighted management’s comments that AI-related optoelectronic components were “completely sold out” through 2029, as Lumentum CEO Michael Hurlston told Bloomberg earlier this month.
The new price target implies roughly 46% upside from Lumentum’s afternoon trading price.
Why Wall Street is bullish on Lumentum
Lumentum, based in San Jose, California, makes lasers and optical components used in telecommunications networks and data centers.
The company has benefited largely from the AI infrastructure boom as tech hyperscalers spend billions of dollars building data centers that require faster connections between servers.
Related: Analysts revamp Super Micro stock price targets after 10% surge on revenue boost
One of its biggest backers is Nvidia (NVDA).
In March, Nvidia announced a multiyear strategic partnership with Lumentum to develop advanced optical technologies for next-generation AI infrastructure.
The agreement includes a multibillion-dollar purchase commitment from Nvidia and rights to access future manufacturing capacity for advanced laser components.
Nvidia also committed to invest $2 billion in Lumentum to support research and development and expand U.S. manufacturing, including a new fabrication facility.
“Together with Lumentum, NVIDIA is advancing the world’s most sophisticated silicon photonics to build the next generation of gigawatt-scale AI factories,” Nvidia CEO Jensen Huang said in the announcement.
StoneX isn’t the only firm optimistic about Lumentum.
On Oct. 20, Jefferies analyst Blayne Curtis raised his price target on Lumentum to $1,250 from $1,200 and maintained a Buy rating.
Curtis expects Lumentum to capture a larger share of Alphabet’s (GOOGL) optical circuit switching demand and benefit from growing adoption of 1.6T transceivers.
Jefferies also expects Lumentum to become Alphabet’s largest optical circuit switch supplier next year, overtaking the tech giant’s in-house production.
Lumentum shares have gained 126% so far in 2026.SOPA Images / Getty Images
Lumentum earnings reflect growing AI demand
Lumentum’s latest quarterly results showed strong demand for its optical networking products.
In its fiscal fourth quarter ended June 27, the company reported revenue of $1.01 billion, up 109.3% from $480.7 million a year earlier. Adjusted earnings rose to $3.23 per share from $0.88 a year earlier.
For fiscal 2026, revenue reached $3.01 billion, compared with $1.6 billion in fiscal 2025.
Also read: Meta stock falls despite Wall Street analysts raising price targets
The company expects fiscal first-quarter 2027 revenue of $1.225 billion to $1.275 billion, with adjusted earnings of $4.05 to $4.35 per share.
Lumentum is scheduled to report its next quarterly results on Nov. 5.
Investors will be watching closely whether the company can expand production quickly enough to meet demand, as well as its outlook for cloud networking revenue and profit margins.
Lumentum shares have gained 126% so far in 2026, as of this writing, although the stock has pulled back sharply from its recent all-time high of $1,143, reached on October 8.
Related: Cathie Wood buys $24.5 million of tumbling megacap stock
McDonald’s new bet on chicken hits a snag as franchisees say the birds are too big
McDonald’s franchisees have complained about “tough meat” and other issues with new hand-breaded chicken, an analyst said.
‘The Wolves Of Real Estate’ Exposes The Dark Side Of Privilege
A disturbing and worthwhile examination of privilege, alleged sexual predation and the long road to accountability.
Kesha’s 16-Year-Old ‘Backstabber’ Video Shows The Value Sitting In Pop’s Vaults
An unreleased clip from the Animal era became a new release moment, and a case study in how catalog gets marketed in 2026.
Walmart’s $184 lab-grown diamond earrings with 18-karat white gold are 43% off
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission.
Why we love this deal
One of my favorite things to look for at estate sales and antique stores is jewelry. You never know what you’re going to find, and when a sparkle catches your eye, it’s like finding hidden treasure. The only thing is, vintage jewelry can be hard to find, and when pieces are available, they will likely be snatched up quickly. Not to mention, they can also be very expensive. If you want the look of vintage jewelry without the hefty price tag, Walmart has a selection with a high-end vibe and affordable prices, some of which have that vintage appeal you might be looking for.
The JeenMata Lab-Grown Diamond Halo Earrings have a vintage-inspired look, and they’re on sale for $104. During a limited-time Flash deal, you can get them for 43% off. If you’re a Walmart member, you get a $5 coupon, saving you more with an even lower sale price of $99. However, these discounts don’t last long, so you’re going to want to grab them while you can.
JeenMata Lab-Grown Diamond Halo Earrings, $104 (was $184) at Walmart
Courtesy of Walmart
Shop at Walmart
Why do shoppers love it?
A luxurious look doesn’t always have to come with a high price tag. These earrings feature a stunning halo design, featuring a 1-carat round-cut lab-grown diamond surrounded by smaller moissanite stones. Each small stone is set with four prongs, adding dimension and shine to an already sparkling pair of earrings. “I love how the single halo gives them a vintage feel with a modern twist,” one shopper said.
The earrings have an equally stunning finish, with 18-karat white gold plated over brass. Not only does the plating cut down on the cost, but it also allows for durability, making them great for everyday wear. If you’re not buying these for yourself, they make a great gift for your loved ones. With the holidays right around the corner, it’s the perfect time to buy them!
Related: Walmart is selling a cozy 2-piece lounge set for $23 in 12 colors
Details to know
Material: Lab-grown diamond, moissanite, and 18-karat white gold over brass.
Shape: Round.
Carats: 1.
According to shoppers, these earrings are “absolutely beautiful.” One reviewer loved them so much, they said, “These earrings have a permanent spot in my jewelry rotation.”
While they may not be natural diamonds, lab-grown diamonds can be virtually identical, minus where they came from. They look so similar, one customer said, “I never thought lab-created diamonds could look this real, but here we are.”
Shop more deals
JeenMata Lab-Grown Diamond Stud Earrings, $89 (was $119) at Walmart
JeenMata Lab-Grown Diamond Drop Earrings, $149 (was $319) at Walmart
JeenMata Lab-Grown Diamond Hoop Earrings, $89 (was $119) at Walmart
The JeenMata Lab-Grown Diamond Halo Earrings have a vintage-style look with an affordable price. On sale for only $104, it’s a limited-time Flash deal you don’t want to miss, whether it’s a gift to yourself or to others.
Investors Are Nervous About the Midterm Elections. Stock Market History Shows You Shouldn’t Be
With tightly contested campaigns leading into November’s midterm elections, it’s no wonder Americans are worried about how the results could impact their portfolios.
According to a Nationwide Retirement Institute study, 75% of investors agree that the outcome of the midterm elections could have a meaningful impact on their long-term financial plans. Additionally, 76% say they believe that if the party they support doesn’t win or maintain control of Congress, it could have significant impacts on the economy.
Historically, however, stocks have performed well in the year following a midterm election cycle.
Must Read
You’re probably eligible to save money on car insurance. Compare rates for your ZIP code with this free — and fast — tool from Money.
Meet your financial goals faster: Take this free, no-obligation quiz to get matched with an advisor today.
These 6 hacks can help seniors save money on things they’re already buying.
“As the big takeaway, [investors] are best off not formulating their investment strategy on political outcomes,” says Gina Martin Adams, chief market strategist at HB Wealth.
Taking a closer look at the current state of the stock market in the lead-up to Election Day can provide a more holistic picture of how the midterms could impact investors’ futures.
Typical stock performance after midterm elections
After hitting a record high on Oct. 6, the S&P 500 experienced an AI-fueled selloff in the middle of the month, slipping by more than 2%. The index has since recovered and is trading less than 1% below its all-time high.
But concerns about a bubble persist. Outside of the mega-cap companies that dominate the index, nearly 40% of the stocks in the S&P 500 are down 20% or more, placing them firmly in bear markets. Yet the odds of the index finishing 2026 in positive territory are currently 89%, according to prediction market platform Kalshi.
Data from Deutsche Bank shows that, in the short term, the stock market has risen in 21 of the last 23 midterm election cycles (from one month before the election to two months after). And in the year following each of the last six midterm elections, the benchmark index has posted a gain:
Nov. 5, 2002, to Nov. 5, 2003: 14.9%
Nov. 7, 2006, to Nov. 7, 2007: 6.7%
Nov. 2, 2010, to Nov. 2, 2011: 3.7%
Nov. 4, 2014, to Nov. 4, 2015: 4.5%
Nov. 6, 2018, to Nov. 6, 2019: 11.7%
Nov. 8, 2022, to Nov. 8, 2023: 14.5%
In half of those instances, the S&P 500’s one-year performance exceeded its long-run average return of 10% dating back to the index’s inception in 1957.
But there are circumstances beyond elections to consider for those years’ underperformances.
In 2006, the midterms were held in the wake of the housing bubble bursting and in the lead-up to the global financial crisis that persisted through 2008. In May 2011, six months after the 2010 election, the S&P 500 declined 19% through October, bottoming just shy of the threshold for a bear market. And in August 2015, nine months after the 2014 election, the index suffered a single-day flash crash of more than 5% in response to slumping Chinese markets and concerns about global economic fallout.
Outliers aside, the index still finished up in those years, which fits a historical pattern.
“Year two, which is the year we’re in during the current presidential cycle, tends to be the weakest [for stocks],” Adams says. “Year three, which follows the midterms, tends to be the strongest.”
Moreover, federal elections land in the fourth quarter, which has seen historically strong performances over the past 13 years. Going back to 2013, the S&P 500 has only finished down in the last quarter of the year once, according to data from Carson Investment Research.
Over that span, the index has had a median return of 6.5%.
How investors should approach the midterms
Nationwide’s study also found that 40% of investors say they made changes to their retirement savings or portfolio in anticipation of the 2026 midterms. That includes 15% of respondents who have moved money into more conservative or lower-risk investments and 13% who diversified into different asset classes or sectors.
But 88% of respondents did not consult a financial advisor about potential election-related risks. Of advisors who were consulted, nearly 1 in 4 warn strongly against making portfolio changes based on election-related anxiety.
“There’s no historical evidence that a meaningful shift in Congress will have a materially stronger impact on markets,” Adams says.
That shift has become commonplace. Since 1894, the party of the president has lost seats in the House of Representatives in all but three midterm elections. In the Senate, that has occurred in two-thirds of midterm elections.
But according to research conducted by HB Wealth in September, that change in the balance of power has been followed by fruitful results for investors.
“In all of the election years in which we’ve had a midterm shift that resulted in a Republican president with a divided government, the next year’s return averaged 17%,” says Adams.
Market-timing typically results in missed gains
On the other hand, investors who altered their strategies in the lead-up to previous elections and attempted to time the market were the most likely to miss out on the S&P 500’s ensuing gains.
Financial services firm Charles Schwab analyzed 80 separate 20-year periods involving five different investing styles. In every scenario, it found that investors who leave money in cash or cash alternatives in the hopes of timing the bottom of a pullback or correction, yet who fail to deploy those funds, perform the worst.
Adams says that this election cycle is unlikely to deviate dramatically from historical precedent. But that doesn’t stop investors from being nervous about the potential impact of midterm elections on their portfolios.
“I think they tend to be over-captivated with policymaking out of Washington as a major market driver,” she says. “It wouldn’t surprise me if investors are letting their political perspective seep into their investment plans.”
More than 6 in 10 advisors who responded to the Nationwide study said that in an election year, the best course of action is not adjusting their or their clients’ investment strategies. That marks an 11-percentage point increase from the 52% of advisors who said the same during the 2024 election cycle.
“[Stocks’ performances] are very persistently positive in the year after a midterm,” Adams says. “In the end, profitability and interest rates are the only two things that really and have extraordinary meaning over time.”
Never miss a Money story.
Join 700,000+ readers who get the latest financial news and advice delivered daily for free. Subscribe to our newsletters.